Investors relished third quarter earnings Wednesday, pumping up shares of Alkermes plc and Dyax Corp., while cooling their outlooks on Gilead Sciences Inc. and Vertex Pharmaceuticals Inc., worried over lower-than-anticipated sales of their top drugs.